Medicare GLP-1 Coverage: The $50 Bridge Program Is Live (2026 Update)

For years, Medicare beneficiaries watched GLP-1 medications transform weight loss for millions of Americans while remaining locked out by a federal prohibition on coverage for obesity drugs. That prohibition ended on July 1, 2026, when the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program and capped monthly copays at $50 for eligible seniors taking FDA-approved GLP-1 medications for weight management. As of November 2026 the program is running, claims are processing, and the first wave of enrollees is hitting its 12-month renewal this month.

The Short Answer

The Bridge Program is live, not pending. Medicare Part D covers FDA-approved GLP-1 weight-loss medications (Wegovy, oral Wegovy, Zepbound, and Foundayo) with copays capped at $50 per month for eligible beneficiaries who enroll. It does not cover compounded or generic copies — only brand-name FDA-approved drugs. If you stay on your current plan, your authorization carries into 2027 after a renewal visit. If you switch plans during open enrollment (October 15 – December 7, 2026), you have to re-enroll under the new plan.

What changed since launch

Status check: November 2026

It was not delayed or rolled back. Enrolled beneficiaries have been filling $50-copay prescriptions since July 1, 2026, and the covered drug list is unchanged.
Annual re-authorization is now real. If you enrolled in June or July 2026, your 12-month renewal falls this month. Skip the re-evaluation visit and the $50 copay stops.
Open enrollment is happening right now. The Annual Enrollment Period runs October 15 through December 7, 2026. Any 2027 plan change means re-applying under the new plan.
Compounded products are still excluded. No compounded semaglutide or tirzepatide through this program, no matter which pharmacy dispenses it.

Why This Is a Historic Shift

Since 2003, Medicare was prohibited by law from covering medications used solely for weight loss. For more than two decades that statutory exclusion meant that even as GLP-1 drugs like Wegovy and Mounjaro demonstrated remarkable efficacy — and even as the FDA approved them specifically for chronic weight management — Medicare beneficiaries paid out of pocket or went without. The Bridge Program finally broke that logjam in July 2026.

The Bridge Program is CMS's first major step toward treating obesity as the chronic disease the medical community now recognizes it to be. It is a direct acknowledgment that GLP-1 medications are not cosmetic treatments but essential therapeutics for metabolic health, cardiovascular risk reduction, and quality of life — and the first four months of claims data are the evidence Congress will use when the pilot comes up for review.

The Numbers Behind the Need

42%

of adults 60+ live with obesity

$1,349

average monthly retail cost of Wegovy before coverage

$50

maximum monthly copay under the Bridge Program, live since July 2026

Which Medications Are Covered?

The Bridge Program covers FDA-approved GLP-1 and dual-agonist medications prescribed for chronic weight management. Here is the covered list as of November 2026 — it has not changed since launch:

Medication	Active Ingredient	Type	Form	Est. Monthly Cost
Wegovy	Semaglutide	GLP-1 agonist	Weekly injection	$50 copay
Wegovy (oral)	Semaglutide 25mg	GLP-1 agonist	Daily pill	$50 copay
Zepbound	Tirzepatide	Dual GIP/GLP-1	Weekly injection	$50 copay
Foundayo	Orforglipron	Oral GLP-1	Daily pill	$50 copay
Mounjaro	Tirzepatide	Dual GIP/GLP-1	Weekly injection	Diabetes coverage standard; weight use not covered

Important: The Bridge Program does NOT cover compounded semaglutide or tirzepatide, nor unapproved generic copies from compounding pharmacies. Only FDA-approved brand-name medications dispensed through licensed retail or specialty pharmacies are eligible. This exclusion held firm through the first four months of the program, so if you are on a compounded product you would need to transition to a covered brand-name drug to receive the $50 copay — and switch back if you ever lose eligibility.

Who Qualifies for the Bridge Program?

Eligibility is more restrictive than commercial insurance coverage. CMS has designed the program to target beneficiaries with the highest clinical need and strongest evidence base for benefit.

Medicare Part D Enrollee

You must be actively enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage plan that includes prescription drug coverage (MA-PD).

BMI Criteria

BMI of 30 or higher (obesity) OR BMI of 27 or higher (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.

Clinical Evaluation

A documented in-person or telehealth evaluation by a licensed prescriber within the 12 months prior to enrollment. The evaluation must include a weight history, comorbidity assessment, and discussion of treatment risks and benefits.

Prior Documentation

Documentation of prior weight loss attempts through lifestyle modification (diet and exercise) for at least 6 months, or documentation of why such attempts were not feasible or effective. This requirement may be waived for patients with BMI over 40 or significant obesity-related complications.

Exclusion Criteria

Patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of pancreatitis, severe gastroparesis, or current pregnancy are excluded from coverage under the Bridge Program.

How to Enroll: Step-by-Step

Enrollment is not automatic, and it does not renew itself. Whether you are applying for the first time or renewing the authorization you got this summer, the process looks like this:

Confirm Your Part D or MA-PD Coverage

Contact your plan directly or check Medicare.gov to confirm your plan is participating in the Bridge Program. Most national plans (UnitedHealthcare, Humana, Aetna, Blue Cross Blue Shield affiliates) are participating for 2027, but smaller regional plans and some MA-PD products still vary — verify before you commit during open enrollment.

Schedule a Clinical Evaluation

If you have not had a weight management visit with a licensed prescriber in the past 12 months, schedule one. This can be done via telehealth or in person. Your prescriber will document your BMI, current weight, comorbidities, and response to treatment so far.

Complete the Bridge Program Enrollment Form

Your prescriber will submit a Bridge Program enrollment form to CMS through your Part D plan. This form includes your BMI, qualifying comorbidities, prior weight management attempts, and attestation that you have been counseled on risks and benefits.

Wait for CMS Approval

CMS has committed to a 14-day turnaround for enrollment decisions, and plans report most first-time applications clear within that window. If you let a renewal lapse, you are back in this queue and pay standard cost-sharing on any fill until it clears — so start the renewal at least three weeks before your authorization expires.

Fill Your Prescription at a Participating Pharmacy

Once approved, your Part D plan will issue a Bridge Program authorization. You can fill your prescription at any in-network retail or specialty pharmacy. The copay will be capped at $50 at the point of sale. Mail-order options are available for most plans.

Annual Re-Authorization

Bridge Program enrollment lasts 12 months. Enrollees from June and July 2026 are in this cycle right now. Complete an annual re-evaluation with your prescriber and re-submit the enrollment form — this is what keeps the $50 copay running into 2027.

What Does This Actually Cost?

The $50 monthly copay cap is the headline number, but understanding your total cost requires looking at the full picture — including plan premiums, deductibles, and any additional fees.

What You Will Pay

$50/month maximum copay for covered GLP-1 medications at in-network pharmacies
$0 for Bridge Program enrollment itself
$0 for annual re-authorization processing
Standard Part D plan premiums continue to apply (varies by plan)

What You Might Still Pay For

Telehealth or office visit copays for your prescriber evaluation (typically $0-$40)
Out-of-network pharmacy fills — you may pay the full cost plus difference
Non-covered medications like compounded products or experimental drugs
Plan deductible still applies if your plan has one before the $50 copay kicks in

Medicare Advantage vs. Original Medicare: What Is Different?

The Bridge Program applies to both Medicare Advantage (Part C) with prescription drug coverage and standalone Part D plans, but there are some practical differences in how enrollment works.

Feature	Original Medicare + Part D	Medicare Advantage (MA-PD)
Enrollment	Direct through CMS.gov or your Part D plan	Through your MA plan's member portal
Prior Authorization	Standard 14-day CMS review	May have additional plan-specific requirements
Pharmacy Network	Broad — any in-network pharmacy	Often narrower — may require specialty pharmacy
Mail Order	Optional through plan's mail service	Often required or strongly incentivized
Copay Cap	$50/month guaranteed	$50/month guaranteed, but may have step therapy rules

Open Enrollment Is Open Right Now: Your 2027 Checklist

The Annual Enrollment Period for 2027 coverage runs October 15 through December 7, 2026. If you are already on a GLP-1 through the Bridge Program, this is the one window where a plan change can quietly cost you your $50 copay. Work through this before you switch anything:

Check the 2027 formulary, not the 2026 one. Plans publish new formularies each fall. Your drug may move tiers or pick up a new prior authorization on January 1.
Confirm the plan still participates. Participation is voluntary per plan and per year. A plan that covered you in 2026 is not obligated to stay in the program for 2027.
Ask about the pharmacy network. Many MA-PD plans push GLP-1s to a single specialty or mail-order pharmacy. An out-of-network fill can mean full retail price.
Plan the re-enrollment, not just the plan switch. New plan means new Bridge Program application, new prescriber form, and a fresh approval. Budget three to four weeks.
Do not leave a gap in treatment. Ask your prescriber to time a refill so you are not waiting on a new authorization with an empty pen.

What If You Do Not Qualify or Need an Alternative?

Not everyone will qualify for the Bridge Program, and not everyone wants brand-name medications. If you fall into any of these categories, compounded GLP-1 medications from a licensed telehealth pharmacy remain a valid and accessible option:

Your current plan does not participate in the Bridge Program for 2027

Your BMI or comorbidity profile does not meet the strict CMS criteria

You prefer an oral or alternative formulation not covered by the Bridge Program

You are under 65 and on Medicare disability (eligibility criteria may differ — check with your plan)

You need to start treatment now rather than wait out an enrollment or re-authorization queue

Need an Alternative Now?

Compounded semaglutide and tirzepatide from Halo-RX are available today at $199/month and $299/month — no insurance required, no open enrollment window, no re-authorization cycle, and no prior authorization. That is roughly what the Bridge Program copay costs, without the yearly paperwork.

Licensed clinician oversight. Discreet home delivery. Same active ingredients as Wegovy and Zepbound.

Start Free Evaluation View Pricing

Frequently Asked Questions

Does Medicare cover Ozempic under the Bridge Program?

Ozempic is FDA-approved for type 2 diabetes, not chronic weight management. The Bridge Program specifically covers medications approved for weight loss: Wegovy, Zepbound, and Foundayo. If you are taking Ozempic for diabetes, it may already be covered under standard Part D rules depending on your plan's formulary. If you are taking it off-label for weight loss, it will not be eligible under the Bridge Program.

Is the Bridge Program actually live, or was it delayed?

It is live and has been since July 1, 2026. Enrollment opened June 1, 2026, and prescriptions filled on or after July 1 have been capped at $50. There was no delay, no suspension and no rollback — as of November 2026 the program is operating normally. If you applied earlier and were told to wait, you can re-check your status now; approvals have been flowing since the summer.

Can I use the Bridge Program with a Medicare Supplement (Medigap) plan?

Medigap plans do not include prescription drug coverage. The Bridge Program requires active Part D or MA-PD enrollment. If you have Original Medicare plus a Medigap plan but no Part D plan, you will need to enroll in a Part D plan to access the Bridge Program. You can do this during the Annual Enrollment Period (October 15 - December 7) or during a Special Enrollment Period if you qualify.

Will the Bridge Program cover retatrutide when it is approved?

CMS has stated that the Bridge Program will be updated to include new FDA-approved GLP-1 and related incretin medications for weight management as they receive approval. Eli Lilly's retatrutide, the triple agonist currently in Phase 3 trials, is expected to be reviewed by the FDA in late 2026 or early 2027. If approved for weight management, it will likely be added to the covered list. The program is designed to be formulary-flexible rather than locked to today's specific drugs.

What happens if I switch Medicare plans during the year?

Bridge Program enrollment is tied to your specific Part D or MA-PD plan. If you switch plans (during the Annual Enrollment Period through December 7, 2026, or a Special Enrollment Period), you must re-enroll in the Bridge Program under your new plan. Your prior authorization does not automatically transfer, and it does not carry across the calendar year on the same plan either — it runs 12 months from your approval, then needs a renewal. Line up the new application before the old authorization expires so you are not paying retail for a fill.

Is the Bridge Program permanent or temporary?

CMS has designated the Bridge Program as a 5-year pilot program running from July 1, 2026 through June 30, 2031. The program will collect data on outcomes, costs, and utilization to inform Congress on whether to make Medicare GLP-1 coverage permanent through legislation. During the pilot period, the $50 copay cap and covered drug list are guaranteed. After 2031, coverage will depend on congressional action and program evaluation data.

Do I need to lose weight on my own before enrolling?

The Bridge Program requires documentation of prior lifestyle modification attempts (diet and exercise) for at least 6 months, or a documented reason why such attempts were not feasible. This does not mean you need to achieve a specific amount of weight loss first — just that you have attempted structured lifestyle change. Your prescriber can document this based on your medical history. Patients with BMI over 40 or severe obesity-related complications may have this requirement waived.

What if my doctor prescribes a dose not covered by my plan?

Some Part D plans may have quantity limits or step therapy requirements (e.g., requiring trial of a lower-cost GLP-1 before covering a higher-cost one). The Bridge Program guarantees $50 copay coverage for all listed medications, but your plan may still apply utilization management rules. If your prescriber believes a specific dose or medication is clinically necessary, they can submit a formulary exception or prior authorization request. The Bridge Program does not override plan-specific quantity limits unless medically justified.

The Bottom Line

Medicare has covered GLP-1 weight loss medications since July 1, 2026

Copays are capped at $50 per month for eligible enrolled beneficiaries

Covered drugs: Wegovy, oral Wegovy, Zepbound, Foundayo, plus future FDA-approved additions

Enrollment is required, is not automatic, and must be renewed every 12 months

Eligibility requires Part D or MA-PD enrollment, BMI criteria, and a prescriber evaluation

The program is a 5-year pilot through 2031; permanent coverage depends on congressional action

The Medicare GLP-1 Bridge Program is a watershed moment for older Americans living with obesity. For the first time, millions of Medicare beneficiaries have affordable access to the most effective weight management medications ever developed. Four months in, the program is working as designed — the catch is the paperwork cadence. With open enrollment open until December 7, 2026, this is the month to check your 2027 formulary and get your renewal visit booked.

If you do not qualify for the Bridge Program, your plan dropped out for 2027, or you would rather skip the annual re-authorization cycle entirely, Halo-RX offers compounded semaglutide and tirzepatide at $199 and $299 per month — with licensed clinician oversight, no insurance, and discreet home delivery.